Skip to main content

Sean McGuire

LTC Bulletin Board
07/20/2015
The FDA approved the Brio Neurostimulation System, a deep brain stimulation device implanted under the skin of the upper chest with electrodes attaching to the brain, to mitigate symptoms of Parkinson’s disease or essential tremor.
The FDA approved the Brio Neurostimulation System, a deep brain stimulation device implanted under the skin of the upper chest with electrodes attaching to the brain, to mitigate symptoms of Parkinson’s disease or essential tremor.
The FDA approved the Brio...
07/20/2015
Annals of Long-Term Care
Managed Care Q&A
08/15/2016
An interview with Jeffrey D Clough, MD, assistant professor of medicine, Duke University School of Medicine.
An interview with Jeffrey D Clough, MD, assistant professor of medicine, Duke University School of Medicine.
An interview with Jeffrey D...
08/15/2016
First Report Managed Care
Managed Care Q&A
07/14/2016
An interview with Michael S Barr, MD, MBA, MACP, executive vice president, NCQA
An interview with Michael S Barr, MD, MBA, MACP, executive vice president, NCQA
An interview with Michael S...
07/14/2016
First Report Managed Care
LTC Bulletin Board
07/20/2015
A group of neurosurgeons revealed promising results for the treatment of brain-related diseases like epilepsy and Alzheimer’s disease.
A group of neurosurgeons revealed promising results for the treatment of brain-related diseases like epilepsy and Alzheimer’s disease.
A group of...
07/20/2015
Annals of Long-Term Care
LTC Bulletin Board
07/20/2015
The FDA has approved Cerebral Assessment Systems Inc.’s Congnivue® device for US distribution.
The FDA has approved Cerebral Assessment Systems Inc.’s Congnivue® device for US distribution.
The FDA has approved Cerebral...
07/20/2015
Annals of Long-Term Care
LTC Bulletin Board
07/20/2015
A recent study has found that targeting synaptic vesicle protein 2A in two transgenic Alzheimer’s disease mouse models (APP/PS1 and 3xTg-AD) can have a therapeutic effect on memory impairment.  
A recent study has found that targeting synaptic vesicle protein 2A in two transgenic Alzheimer’s disease mouse models (APP/PS1 and 3xTg-AD) can have a therapeutic effect on memory impairment.  
A recent study has found that...
07/20/2015
Annals of Long-Term Care
LTC Bulletin Board
07/20/2015
A new treatment approach administers medication deep within the brain through an electronic micropump to target the specific cells that cause seizures.
A new treatment approach administers medication deep within the brain through an electronic micropump to target the specific cells that cause seizures.
A new treatment...
07/20/2015
Annals of Long-Term Care
LTC Bulletin Board
07/20/2015
A team of scientists from Johns Hopkins University (Baltimore, MD) may have identified an amino acid with the potential to inhibit seizures.
A team of scientists from Johns Hopkins University (Baltimore, MD) may have identified an amino acid with the potential to inhibit seizures.
A team of scientists from Johns...
07/20/2015
Annals of Long-Term Care
LTC Bulletin Board
07/20/2015
Despite the fact that over 8,400 patients die per year from oral cavity and pharynx cancers—most of whom are over the age of 65—the costs associated with these illnesses are not well understood. 
Despite the fact that over 8,400 patients die per year from oral cavity and pharynx cancers—most of whom are over the age of 65—the costs associated with these illnesses are not well understood. 
Despite the fact that over 8,400...
07/20/2015
Annals of Long-Term Care